Form 4: Amphastar Director Receives Equity Grant

Director David Russell Gaugh was granted 8,143 restricted stock units and 17,365 stock options by Amphastar Pharmaceuticals.

Summary

• Director David Russell Gaugh acquired 8,143 restricted stock units (RSUs) on June 1, 2026.
• The director also received a grant of 17,365 stock options with an exercise price of $18.42.
• Both the RSUs and the stock options are scheduled to vest in full on June 1, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Retention of key board leadership through multi-year vesting schedules.

Negatives

• Potential for future shareholder dilution upon the exercise of stock options and vesting of RSUs.

Risks

• Market price volatility affecting the value of the granted equity instruments.
• Performance risk associated with the company's ability to maintain share price above the $18.42 exercise price.

Future Outlook

The equity grants indicate a standard compensation structure for board members, with full vesting occurring one year from the grant date.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard practice in the pharmaceutical industry to ensure long-term alignment with corporate governance and strategic objectives.

Comparison to Industry Standards

• The use of time-based vesting for director equity is consistent with standard corporate governance practices for mid-cap pharmaceutical companies.
• The grant size is commensurate with typical director compensation packages for companies of similar market capitalization.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of options and vesting of RSUs.

Next Steps

• Vesting of equity grants on June 1, 2027.

Key Dates

Keywords

Amphastar Pharmaceuticals, AMPH, Form 4, Insider Transaction, Equity Compensation, Director Compensation